Norberto C. Tapia-Chavez

Puente De Piedra 150, C.P. 14050
Toriello Guerra, DIF 14050, Mexico

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 110 publications

Global multicenter validation of noninvasive fibrosis assessment pathways in MetALD and ALD.

Global multicenter validation of noninvasive fibrosis assessment pathways in MetALD and ALD.

Journal: Hepatology communications

Published: February 25, 2026

Reframing MASLD: A Hepatic Condition With Systemic Clinical Impact.

Reframing MASLD: A Hepatic Condition With Systemic Clinical Impact.

Journal: Journal of clinical and experimental hepatology

Published: January 14, 2026

Risk score to predict fibrosis among Mexican adults: results of the Health Workers Cohort Study.

Risk score to predict fibrosis among Mexican adults: results of the Health Workers Cohort Study.

Journal: Frontiers in medicine

Published: October 14, 2025

Predictors of mortality and liver transplant requirement in patients with hepatitis A virus: A case series from Mexico.

Predictors of mortality and liver transplant requirement in patients with hepatitis A virus: A case series from Mexico.

Journal: World journal of gastrointestinal surgery

Published: August 06, 2025

Epidemiology and etiologic trends of hepatocellular carcinoma in cirrhotic patients in Mexico: a multicenter retrospective study (2018-2024).

Epidemiology and etiologic trends of hepatocellular carcinoma in cirrhotic patients in Mexico: a multicenter retrospective study (2018-2024).

Journal: Annals of hepatology

Published: June 25, 2025

Thoughts on "Noncontrast Magnetic Resonance Imaging vs Ultrasonography for Hepatocellular Carcinoma Surveillance".

Thoughts on "Noncontrast Magnetic Resonance Imaging vs Ultrasonography for Hepatocellular Carcinoma Surveillance".

Journal: Gastroenterology

Published: June 16, 2025

Hemostatic alterations in metabolic dysfunction-associated steatotic liver disease (MASLD) and their link to venous thromboembolism (VTE).

Hemostatic alterations in metabolic dysfunction-associated steatotic liver disease (MASLD) and their link to venous thromboembolism (VTE).

Journal: Thrombosis research

Published: May 13, 2025

The pathophysiological link between type 1 diabetes and MASLD: insights into insulin resistance and liver dysfunction.

The pathophysiological link between type 1 diabetes and MASLD: insights into insulin resistance and liver dysfunction.

Journal: Journal of endocrinological investigation

Published: May 07, 2025

Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies.

Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies.

Journal: International journal of molecular sciences

Published: February 24, 2025

Changing Landscape of Liver Cirrhosis Etiologies.

Changing Landscape of Liver Cirrhosis Etiologies.

Journal: Archives of medical research

Published: February 06, 2025

To Continue or Discontinue β-Blockers in Secondary Prophylaxis? That is the Dilemma.

To Continue or Discontinue β-Blockers in Secondary Prophylaxis? That is the Dilemma.

Journal: The American journal of gastroenterology

Published: July 16, 2024

Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial.

Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial.

Journal: Journal of intensive medicine

Published: April 02, 2024

Showing 1-12 of 110

Last Updated: 09/26/2026